KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Prepaid Assets (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Prepaid Assets readings, the most recent being $4.0 million for Q4 2025.

  • On a quarterly basis, Prepaid Assets fell 2.67% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 2.67% decrease, with the full-year FY2025 number at $4.0 million, down 2.67% from a year prior.
  • Prepaid Assets hit $4.0 million in Q4 2025 for Esperion Therapeutics, up from $2.8 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $34.2 million in Q1 2021 to a low of $504000.0 in Q1 2025.
  • Median Prepaid Assets over the past 5 years was $8.0 million (2022), compared with a mean of $8.5 million.
  • Biggest five-year swings in Prepaid Assets: soared 1312.92% in 2022 and later crashed 95.54% in 2025.
  • Esperion Therapeutics' Prepaid Assets stood at $11.2 million in 2021, then fell by 11.7% to $9.9 million in 2022, then tumbled by 54.32% to $4.5 million in 2023, then fell by 7.81% to $4.2 million in 2024, then decreased by 2.67% to $4.0 million in 2025.
  • The last three reported values for Prepaid Assets were $4.0 million (Q4 2025), $2.8 million (Q3 2025), and $5.4 million (Q2 2025) per Business Quant data.